Comprehensive Investigation of Stereoselective Food Drug Interaction Potential of Resveratrol on Nine P450 and Six UGT Isoforms in Human Liver Microsomes

被引:9
作者
Ji, Seung-Bae [1 ,2 ]
Park, So-Young [1 ,2 ]
Bae, Subin [1 ,2 ]
Seo, Hyung-Ju [1 ,2 ]
Kim, Sin-Eun [1 ,2 ]
Lee, Gyung-Min [1 ,2 ]
Wu, Zhexue [2 ,3 ]
Liu, Kwang-Hyeon [1 ,2 ,3 ]
机构
[1] BK21 Four KNU Community Based Intelligent Novel D, Daegu 41566, South Korea
[2] Coll Pharm, Res Inst Pharmaceut Sci, Daegu 41566, South Korea
[3] Kyungpook Natl Univ, Mass Spectrometry Based Convergence Res Inst, Daegu 41566, South Korea
关键词
cytochrome P450; food drug interactions; resveratrol; stereoselectivity; uridine 5 '-diphosphoglucuronosyl transferase; IN-VITRO; TRANS-RESVERATROL; RED WINE; CYTOCHROME-P450; ENZYMES; DIFFERENTIAL INHIBITION; DEPENDENT INHIBITION; PHARMACOKINETICS; MECHANISM; GLUCURONIDATION; DEBRISOQUINE;
D O I
10.3390/pharmaceutics13091419
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The stereoselectivity of the food drug inhibition potential of resveratrol on cytochrome P450s and uridine 5'-diphosphoglucuronosyl transferases was investigated in human liver microsomes. Resveratrol enantiomers showed stereoselective inhibition of CYP2C9, CYP3A, and UGT1A1. The inhibitions of CYP1A2, CYP2B6, and CYP2C19 by resveratrol were stereo-nonselective. The estimated K-i values determined for CYP1A2 were 13.8 and 9.2 mu M for trans- and cis-resveratrol, respectively. Trans-resveratrol noncompetitively inhibited CYP3A and UGT1A1 activities with K-i values of 23.8 and 27.4 mu M, respectively. Trans-resveratrol inhibited CYP1A2, CYP2C19, CYP2E1, and CYP3A in a time-dependent manner with K-i shift values >2.0, while cis-resveratrol time-dependently inhibited CYP2C19 and CYP2E1. The time-dependent inhibition of trans-resveratrol against CYP3A4, CYP2E1, CYP2C19, and CYP1A2 was elucidated using glutathione as a trapping reagent. This information helped the prediction of food drug interaction potentials between resveratrol and co-administered drugs which are mainly metabolized by UGT1A1, CYP1A2, CYP2C19, CYP2E1, and CYP3A.
引用
收藏
页数:15
相关论文
共 63 条
  • [1] AMERICANHS.ORG, BEST ER DYSF PILLS M
  • [2] [Anonymous], Resveratrol
  • [3] Anti-tumor activity of resveratrol against gastric cancer: a review of recent advances with an emphasis on molecular pathways
    Ashrafizadeh, Milad
    Rafiei, Hossein
    Mohammadinejad, Reza
    Farkhondeh, Tahereh
    Samarghandian, Saeed
    [J]. CANCER CELL INTERNATIONAL, 2021, 21 (01)
  • [4] Awortwe Charles, 2015, Drug Metab Lett, V9, P48
  • [5] Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: Comparison with grapefruit juice
    Bailey, DG
    Dresser, GK
    Bend, JR
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (06) : 529 - 537
  • [6] Wine Resveratrol: From the Ground Up
    Bavaresco, Luigi
    Lucini, Luigi
    Busconi, Matteo
    Flamini, Riccardo
    De Rosso, Mirko
    [J]. NUTRIENTS, 2016, 8 (04):
  • [7] Resveratrol Pretreatment Affects CYP2E1 Activity of Chlorzoxazone in Healthy Human Volunteers
    Bedada, Satish Kumar
    Neerati, Prasad
    [J]. PHYTOTHERAPY RESEARCH, 2016, 30 (03) : 463 - 468
  • [8] Effect of Resveratrol on the Pharmacokinetics of Carbamazepine in Healthy Human Volunteers
    Bedada, Satish Kumar
    Nearati, Prasad
    [J]. PHYTOTHERAPY RESEARCH, 2015, 29 (05) : 701 - 706
  • [9] Resveratrol in Cancer Patients: From Bench to Bedside
    Berretta, Massimiliano
    Bignucolo, Alessia
    Di Francia, Raffaele
    Comello, Francesco
    Facchini, Gaetano
    Ceccarelli, Manuela
    Iaffaioli, Rosario Vincenzo
    Quagliariello, Vincenzo
    Maurea, Nicola
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (08)
  • [10] The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective
    Bjornsson, TD
    Callaghan, JT
    Einolf, HJ
    Fischer, V
    Gan, L
    Grimm, S
    Kao, J
    King, SP
    Miwa, G
    Ni, L
    Kumar, G
    McLeod, J
    Obach, RS
    Roberts, S
    Roe, A
    Shah, A
    Snikeris, F
    Sullivan, JT
    Tweedie, D
    Vega, JM
    Walsh, J
    Wrighton, SA
    [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (07) : 815 - 832